ticagrelor

Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

Deshydroxyethoxy ticagrelor (AR-C124910) is a metabolite of Ticagrelor that exhibits antibacterial activity against MRSA and possesses antiplatelet effects.

Ticagrelor-D7 (Standard) is a reference standard of Ticagrelor-D7 intended for quantitative analysis, quality control, and related biochemical research applications. Ticagrelor-d7 is a deuterated compound of Ticagrelor. Ticagrelor has a CAS number of 274693-27-5. Ticagrelor, produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

Ticagrelor metabolite M5 (T437700) is a metabolite of Ticagrelor, the first reversible oral antagonist of P2Y12 receptor. Compared to Clopidogrel, Ticagrelor has faster and more consistent inhibition on ADP-receptors. Ticagrelor is used in the treatment of acute coronary syndromes (ACS).

Ticagrelor impurity 5 is an impurity of Ticagrelor.

Ticagrelor impurity 7 is an impurity associated with Ticagrelor.

Ticagrelor impurity 16 is a by-product associated with Ticagrelor.

Ticagrelorimpurity 21 is a type of Ticagrelor impurity.

Ticagrelor impurity 2 is a contaminant associated with Ticagrelor.

Ticagrelorimpurity 25 is an impurity associated with Ticagrelor.

Ticagrelor impurity 89 is a known impurity of Ticagrelor.

Ticagrelorimpurity 11 is an impurity found in Ticagrelor.

Ticagrelor Impurity 6 is a known impurity of Ticagrelor.

Ticagrelorimpurity 19 is an impurity associated with Ticagrelor.

Ticagrelor impurity 10 is a type of Ticagrelor impurity.

Ticagrelor impurity 26 is an impurity associated with Ticagrelor.

Ticagrelor impurity 8 is an impurity associated with the compound Ticagrelor.

Ticagrelorimpurity 22 is an impurity of Ticagrelor.

Ticagrelor impurity 14 is a known impurity of Ticagrelor.

Ticagrelor Impurity 27 is an impurity associated with Ticagrelor.

Ticagrelor impurity 12 is an impurity of Ticagrelor.

Ticagrelor impurity 3 is an impurity found in Ticagrelor.

Ticagrelor-D7 is a deuterated compound of Ticagrelor. Ticagrelor (T0179) has a CAS number of 274693-27-5. Ticagrelor, produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique (EU) and Possia (EU).

Ticagrelor (Standard) is a reference standard for research and analysis in studies involving Ticagrelor. Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).